Granite Point Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Granite Point Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-80,000	Closed	-$1.75M	–	130
2017 Q4	$1.75M	Buy	80,000 +30,000	+60%	+$965K	0.17%	36
2017 Q3	$2.05M	Buy	50,000 +20,000	+67%	+$628K	0.43%	29
2017 Q2	$903K	Hold	30,000	–	–	0.22%	64
2017 Q1	$1.08M	Buy	+30,000	New	+$1.32M	0.32%	43
2015 Q4	$1.91M	Buy	+45,900	New	+$1.54M	0.29%	25
2014 Q3	–	Sell	-40,000	Closed	-$622K	–	105
2014 Q2	$622K	Sell	40,000 -17,600	-31%	-$252K	0.43%	55
2014 Q1	$1.13M	Buy	57,600 +37,600	+188%	+$638K	0.81%	37
2013 Q4	$336K	Buy	+20,000	New	+$249K	0.06%	91

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Granite Point Capital Management's FPRX Position: Q1 2018 in Review

Granite Point Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2018, closing a stake of 80,000 shares — an estimated $1.75M sold.

Granite Point Capital Management first reported a position in FPRX in Q4 2013 and held it in 8 quarters. The position peaked at $2.05M in Q3 2017. 128 funds tracked by Wall St. Rank hold FPRX as of Q1 2018.

Granite Point Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Granite Point Capital Management sold 80,000 Five Prime Therapeutics, Inc. shares in Q1 2018, an estimated $1.75M.
Granite Point Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 8 quarters.
Granite Point Capital Management's Five Prime Therapeutics, Inc. position peaked at $2.05M in Q3 2017.
128 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2018.

Based on Granite Point Capital Management's 13F filing for Q1 2018, filed 15 May 2018.